YS110

YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS[1][2][3].

Product Specifications

CAS Number

[1656248-21-3]

UNSPSC

12352203

Target

Dipeptidyl Peptidase; ERK; p38 MAPK

Related Pathways

MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

References & Citations

[1]Hayashi M, et al. A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition. Cancer Cell Int. 2016 Apr 30;16:35. |[2]Yamada K, et al. Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription. PLoS One. 2013 Apr 29;8 (4) :e62304.|[3]Ohnuma K, et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol. 2013 Dec;87 (24) :13892-9.